The measure is intended to require some community health centers to provide savings to low-income patients.
The White House this week gave President Biden the green light to move forward with removing a Trump-era health care policy designed to lower the price of insulin.
Biden’s bid to roll back the rule was approved on Monday, as reported politician, with the expectation that the Department of Health and Human Services may publish the return in the coming days.
The measure, signed under a previous administration in December, is aimed at requiring some 340B community health centers to provide savings for insulin and epinephrine to low-income patients in a bid to bring down unaffordable prices.
Spokespersons for the White House and the Department of Health and Human Services did not return Granthshala Business’s request for comment.
The rule was supposed to come into force in January, but was put on hold at that time.
Earlier this year, the National Association of Health Care Centers said the rule would “adversely impact community health centers” and make it harder for low-income patients to afford medicines.
Get Granthshala Business on the go by clicking here
President Donald Trump focused on lowering the price of drugs during his term. Biden has made similar promises, including allowing Medicare to negotiate lower prices for prescription drugs.